AffinityImmuno Inc. named as one of eight semi-finalists to present at the virtual BioInnovation Challenge pitch event

Emergence client AffinityImmuno Inc. has been named as one of eight semi-finalists to compete in the 10th annual BioInnovation Challenge (BIC), BioNova’s regional health and life sciences business competition, which will be held virtually on November 3rd and 4th during BioPort 2020.

BIC is one of the longest running business competitions in the region with over 50 companies having gone through the program since 2011. Many of the companies coming out of the program have gone on to raise millions to grow and scale. ABK BioMedical, the first place winner of BIC 2011, raised a record-setting $30M USD venture capital round in 2019.

Semi-finalists will receive significant training to be positioned for business growth, including sessions with expert pitch training coach Linda Plano, who has over ten years of experience mentoring entrepreneurs with start-ups in life sciences. This year’s winner will receive $25,000 in funding to develop their business idea as well as a package of support services and mentoring valued at more than $30,000.

Learn more about the eight (8) semi-finalists who will be pitching virtually on November 3rdduring BioPort 2020:

AffinityImmuno Inc. – PEI
Jonathan Zuccolo, Founder
AffinityImmuno Inc. has developed a novel serum test to meet the challenge of monitoring development of immunity to the ongoing SARS-CoV-2 pandemic. The virus neutralization test monitors vaccine responses, population spread of a virus, and length of immune response.

3D BioFibR – NS
Kevin Sullivan, CEO
3D BioFibR technology is a platform technology capable of creating a variety of high value biofibres. Its
collagen fibres have properties resembling the human body. In the lab, this material can be used to create a highly consistent scaffold for 3D tissue culture. In medicine, this material can be doped with antimicrobial agents and drugs to promote wound healing, producing a bandage that can seal a wound.

Clever Fruit Products – NS
Liam Tayler, President
Clever Fruit Products has developed proprietary fermentation technologies which create a product that improves the bioavailability of fruit polyphenols. The company is seeking to maximize the nutritional potential of Nova Scotian wild blueberry, and aid in people’s access to their many health benefits.

eNable Analytics – NB
Alex Roberts
eNable Analytics is a data-centric machine learning company that has developed an innovative platform that turns assistive devices (canes, walkers, and rollators) into remote monitoring tools. Combined with innovative machine learning-based analyses, they provide regular and proactive insights about the physical and behavioural health of users.

Greenlight Analytical – NS
Dr. James Wylde, President & CEO
Greenlight Analytical will be advancing their chemical analyzer, initially designed for safety and quality control of cannabis crops, to extend its capability to detect toxins in illicit narcotics. The portability and ease-of-use will allow the instrument to be used by first responders to identify the presence of toxins, such as fentanyl, in a medical emergency (overdose) and allow them to take appropriate safety measures to avoid contamination or exposure.

Parados Cerebral Solutions – NB
Pascal McCarthy, CEO
Parados is developing a mouth guard with sensors that will allow athletes to know whether they have sustained a head injury that is likely to lead to a concussion. Over time, an artificial intelligence system will be able to offer insights into the cumulative effects athletes face when they suffer repeated brain injuries.

Swiftsure Innovations – NF
Deanne McCarthy (RN), CEO & Founder
The Complete Care Endotracheal Tube (CCET), patent pending, is a novel endotracheal tube that will revolutionize oral care for mechanically ventilated patients. CCET is the first medical device that allows for large volume nasal and oral irrigation of patients on life support without risk of aspiration or tissue injury, while simultaneously limiting the production of aerosols.

Symbi Medical – NS
Cameron Sehl, CEO & Co-founder
Symbi is a cloud-based remote patient monitoring system for GI care. Symbi creates personalized care plans for each patient to follow in-between appointments and uses text messaging to monitor patients throughout each stage of their care and identify those who are at higher risk of health complications.

BIC 2020 is presented by BioNova in partnership with the Atlantic Canada Opportunities Agency, BioNB, Emergence, Gallagher Insurance, Cox & Palmer, Jennifer Cameron PR, and Bereskin & Parr.

BIC 2020 will take place over two days in November. The eight (8) semi-finalists will present to a panel of judges and the conference audience during BioPort’s virtual conference, on November 3rd. The top three presenters will then pitch virtually the following morning.  The winner will be announced at the close of BioPort 2020 on the afternoon of November 4th.

Posted in Uncategorized

Ahiflower oil receives Canadian novel foods approval

Emergence client Natures Crops International has announced that the Health Canada Food Directorate has approved Ahiflower® oil for use in foods in Canada. This is according to a letter of no objection dated July 17th, 2020 received by Natures Crops International.

Greg Cumberford, VP Science & Regulatory, stated, “Natures Crops is delighted for Ahiflower oil, which is produced in Prince Edward Island at our dedicated refinery, to now be available in foods and beverage products widely in Canada. Ahiflower oil provides a unique balance of omega fatty acids and its clean taste and aroma make it ideal for brands seeking to improve omega-3 levels from a regenerative plant-based source.”

According to Health Canada’s Bureau of Nutritional Sciences, characterizing the work performed to assess Ahiflower oil’s safety, “Scientists at Health Canada with expertise in molecular biology, microbiology, toxicology, chemistry, and nutrition conducted a thorough analysis of the data and the protocols provided by the applicant to ensure the validity of the results. To ensure that the Ahiflower® oil is safe for consumption, the scientists considered how the products were developed, their composition, whether they could be toxic or cause allergic reactions, and their dietary exposure in the Canadian population. Following this assessment, it was determined that the use of Ahiflower® oil is safe as an ingredient for use in foods and beverages at a level providing up to 375 mg stearidonic acid per serving of food.”

Ahiflower oil is the richest-available natural source of omega-3 stearidonic acid and omega-6 gamma linolenic acid in a dietary oil. Health Canada’s allowed limit translates to approximately 2 grams Ahiflower oil per serving in a wide range of foods including dairy and dairy analog beverages, vegetable and fruit juices, oils and dressings, sauces, baked goods, snack foods, soups, and soft candy.

Ahiflower oil is grown and manufactured exclusively by Natures Crops International. For more information, please visit www.ahiflower.com.

Posted in News

3 reasons Emergence companies should apply for the BioInnovation Challenge

Now in its tenth year, the BioInnovation Challenge (BIC) is a pitching competition for early-stage life sciences companies in Atlantic Canada. BIC was created by BioNova to help ease the transition from research to market and recognize the significant commercialization potential of the bioscience sector in Atlantic Canada.

Last year, three Emergence companies were semi-finalists in the BIC: AffinityImmuno and Fieldetect of Prince Edward Island, and Dr. A.K. Gordon of Nova Scotia. This year’s finalists will present at BioPort 2020 in November.

Here are three reasons you should consider applying:

1. Access to funding
The winner of the pitch competition will be awarded $25,000 in funding to help develop their business and a $30,000 advisory services package. Since its inception in 2011, BIC has provided more than $300K in grand prize package value to accelerate start-ups.

2. Pitch training and business development
BIC participants receive pitching and business training to help position their company for continued growth. BIC also connects finalists with investors, the media and industry influencers. Take advantage of the spotlight and kick-start your success.

3. Applying is easy
Deadline for applications is Friday, August 7, 2020. Email kmannette@bionova.ca to receive a copy of the application.

Emergence is a proud supporter of BIC. For more information on the program, visit their website.

Posted in Clients, News

Auxly’s Subsidiary Dosecann Enters into Manufacturing and Distribution Agreement with dosist™, an Award-Winning Wellness Company

TORONTO, June 24, 2020 (GLOBE NEWSWIRE) — Auxly Cannabis Group Inc. (TSX.V – XLY) (“Auxly” or the “Company”), a leading consumer packaged goods company in the derivative cannabis products market, is pleased to announce that its wholly-owned subsidiary Dosecann LD Inc. (“Dosecann”) has entered into an agreement with GSW Creative Corporation Canada Inc., doing business as dosist (“dosist”), to manufacture their proprietary wellness vape devices at Dosecann’s facility in Prince Edward Island.

Dosecann will utilize its production capabilities, capacity, and world-class expertise in cannabis derivative products to manufacture dosist’s innovative dose control solutions. dosist will also utilize Auxly’s well-established national distribution channels to bring its proprietary new innovations to Canadians nation-wide, including their newly engineered dose pen 100, their new range of high potency formulas for THC-forward experiences called thc-plus, and their new rechargeable dose pen system. To view the full press release, link here.

Posted in Clients, News

SP Nutraceuticals Launches First Avocado-based Supplement Metavo to Target Insulin Resistance, Support Healthy Metabolism

Metavo contains AvoB, a powerful bioactive discovered by Canadian scientists and  known to support healthy metabolism, blood sugar levels and weight in adults

SP Nutraceuticals (SP), as part of its mission to build healthy communities through plant-based nutrition backed by rigorous science, is proud to announce the launch of Metavo, a natural supplement that contains avocatin B (AvoB). AvoB is a powerful bioactive naturally found in avocados that helps maintain normal blood glucose (sugar) levels and supports healthy metabolism.

In collaboration with a team of nutritional scientists from the University of Guelph lead by renowned nutraceutical expert and researcher, Dr. Paul Spagnuolo, conducted extensive research and identified and isolated the new bioactive. AvoB can be used to maintain a healthy metabolism, blood sugar levels and weight in adults naturally, effectively and safely. It is particularly beneficial for those who are looking to manage blood sugar levels, those who are pre-diabetic, obese or overweight.

Continue reading

Posted in Clients, News

Join us in welcoming Robin Muzzerall, Facility Manager, CAT Victoria-PEI Plant

Robin Muzzerall, Facility Manager, CATC Victoria-Prince Edward Island Plant

The Emergence community welcomes Robin Muzzerall as she begins her new role as Facility Manager at the CAT Victoria-PEI Plant. As Facility Manager, Robin will oversee operations of the newly acquired facility in Victoria by the Sea. The recent acquisition of the 46,000 sq ft campus, which houses both aquatic and dry lab space, will triple the Canadian footprint for the Center for Aquaculture Technologies (CAT) and make it the largest aquaculture CRO in the world with BSL3 containment certification. Robin brings extensive skills to the position with more than 25 years of leadership experience in the Canadian Aquaculture Industry.  She will play a critical role in helping CAT scale its service-orientated activities and further enhance its global reputation while championing innovation within Aquaculture and Bioscience related industries. After sharing her passion for aquaculture across the country, she is thrilled to return home to the Maritimes to establish strong ties with the local community of Victoria and join the thriving bioscience sector on beautiful Prince Edward Island.

Robin’s bio:

Robin was introduced to the culture of lobster while completing her BSc. Biology at St. Mary’s University in Halifax. Following graduation, having an interest in growing livestock, Robin began her aquaculture career on the east coast. Early on this included supervising the wet lab and managing trials for Aqua Health Ltd., in PEI. Following that time Robin has spent more than 25 years as a hands-on manager in freshwater production of salmon and arctic char including responsibilities of broodstock management, egg, fry and smolt production for internal and external customers. She has worked on both coasts and in the north. Robin has also been an integral part of several facility projects including retrofits, new builds and commissioning of new systems.

Robin’s management experience and style is one that encourages growth and development of the skills of others to promote the success of the operation. Robin also sees the value of community engagement to promote the industry.

Robin returned to PEI to join CATC in May 2020, almost full circle to where she began her interest and career in aquaculture.

Connect with Robin on LinkedIN: https://www.linkedin.com/in/robin-muzzerall-20337343/

Follow news from Center for Aquaculture Technologies on LinkedIN: https://www.linkedin.com/company/center-for-aquaculture-technologies/

Related story:

CATC acquires research facility

Posted in Careers, Clients, Leaders

Alpha Cognition Inc. announces granted EU patents and orphan drug designation for its Progranulin platform

Emergence client Alpha Cognition Inc. (ACI) [formerly Neurodyn Cognition], a clinical stage biotherapeutics company, announced today it has been granted two EU patents (EP2249861A1 and EP3009143A1) relating to the treatment of neurodegenerative diseases using progranulin.  Additionally, the FDA, has granted ACI Orphan Drug Designation for its progranulin product platform for the treatment of amyotrophic lateral sclerosis (ALS). Alpha Cognition operates its laboratory facilities in the Prince Edward Island Bioscience Cluster, Canada.

Alpha-602, progranulin, is a protein that has a potent ability to protect neurons that are under stress. In pre-clinical studies, ACI has demonstrated that progranulin can correct the cellular defects caused by the altered patterns of proteins in motor neurons.  ACI is developing a specific form of progranulin, called Alpha-602, for the treatment of ALS patients.

ACI’s growing list of granted patents now includes two more in Europe.  These patents relate to methods and compositions for the treatment of neurodegenerative diseases using progranulin, and methods of treatment of neurodegenerative diseases using effectors, or combinations of effectors, that modify progranulin expression.

The Orphan Drug Act (ODA) provides special incentives for the development of treatments for rare diseases, such as ALS. For a drug to qualify for orphan-drug designation both the drug and the disease must meet certain specified criteria.  In Q1 of 2020, the FDA granted orphan-drug designation to Alpha-602 for the treatment of ALS.  Alpha-602, is currently advancing through pre-clinical development and toxicology programs.

ACI’s Chief Scientific Officer, Dr. Denis Kay, stated, “These granted patents, together with the orphan-drug designation, mark significant milestones in the clinical development path of Alpha-602 for the treatment of ALS.”

For additional information about the Company and its research programs, visit the Company’s website at http://www.alphacognition.com. 

About Alpha Cognition Inc. – Alpha Cognition Inc. (ACI) is engaged in neurological disease research and has developed programs in Alzheimer’s Disease and amyotrophic lateral sclerosis (ALS).

  • Alpha-1062 is a patented new chemical entity that has shown efficacy in preclinical and recently completed human clinical trials. It is being developed as a new generation acetylcholine esterase inhibitor (AChEI) with minimal gastrointestinal side effects and new routes of administration. Alpha-1062’s active metabolites are differentiated from donepezil and rivastigmine in that they may sensitize neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition.
  • Alpha-602 (Progranulin) is a natural protein that is expressed in several cell types in the central nervous system and in peripheral tissues. Alpha-602 regulates cell survival and certain inflammatory processes. The protein plays a major role in regulating lysosomal function and microglial responses to disease. Its use in the treatment of ALS has been patented by ACI.

For additional information about this press release contact:  rcarpenter@alphacognition.com

For additional information about the company contact:  info@alphacognition.com

Or write to:

Investor Relations
Alpha Cognition Inc.
439 Helmcken Street,
Vancouver, B.C. V6B 2E6

Posted in Clients

Alpha Cognition Inc. Receives FDA/PMDA Regulatory Guidance for Alpha-1062 Alzheimer’s Therapy

April 30, 2020– [Emergence Client] Alpha Cognition Inc. (ACI) [formerly Neurodyn Cognition] today announced that in a pre-Investigational New Drug (Pre-IND) meeting, the U.S. Food and Drug Administration (USFDA) agreed upon a clinical and regulatory pathway for the approval of Alpha-1062, a patented new chemical entity, to treat Alzheimer’s disease.  The FDA has suggested that a single pivotal trial, scheduled for mid 2021, may be sufficient to obtain marketing approval.  ACI also met with Japan’s Pharmaceutical and Medical Devices Agency (PMDA) earlier this year, who also agreed to consider a similar pathway for approval in Japan.

This follows an earlier press release announcing ACI’s partnership with Linical, a Japanese based contract research organization who will provide regulatory consulting and strategic development services, including post-marketing studies, for Alpha-1062 in Japan.

ACI’s Director of Regulatory Affairs, Mrs.Colleen Johns, commented that, “We are pleased with the responses we received from the FDA and the PMDA” She went on to say, “With the confirmation from the FDA that our suggested pathway is acceptable, we are well-positioned to progress the program quickly and efficiently to approval.”

Alpha-1062 is being developed in both an oral tablet and nasal spray format. Clinical trials have demonstrated that, the intranasal formulation showed a decrease of over 90% in GI related adverse events compared to an approved AChEI (Razadyne®) at similar dose levels.

For additional information about the Company and its research programs, visit the Company’s website at http://www.alphacognition.com.

About Alpha Cognition Inc. – Alpha Cognition Inc. (ACI) is engaged in neurological disease research and has developed programs in Alzheimer’s Disease and amyotrophic lateral sclerosis (ALS).

  • Alpha-1062 is a patented new chemical entity that has shown efficacy in preclinical and recently completed human clinical trials. It is being developed as a new generation acetylcholine esterase inhibitor (AChEI) with minimal gastrointestinal side effects and new routes of administration. Alpha-1062’s active metabolites are differentiated from donepezil and rivastigmine in that they may sensitize neuronal nicotinic receptors, most notably the alpha-7 subtype, which may have a positive effect on the disease.
  • Alpha-602 (Progranulin) is a natural protein that is expressed in several cell types in the central nervous system and in peripheral tissues. Alpha-602 regulates cell survival and certain inflammatory processes. The protein plays a major role in regulating lysosomal function and microglial responses. Its use in the treatment of ALS has been patented by ACI and is being investigated in preclinical models.

For additional information about this press release contact:  rcarpenter@alphacognition.com

For additional information about the company contact:  info@alphacognition.com

Or write to: Investor Relations

Alpha Cognition Inc.
439 Helmcken Street,
Vancouver, B.C. V6B 2E6

Posted in Clients, News

Auxly’s Subsidiary Dosecann Signs Key Supplier Agreement With Medical Cannabis by Shoppers

Auxly Cannabis Group Inc. (TSX.V – XLY) (“Auxly” or the “Company”), a leading consumer packaged goods company in the derivative cannabis market, is pleased to announce that its wholly-owned subsidiary Dosecann LD Inc. (“Dosecann”) has entered into an agreement with Medical Cannabis by Shoppers Drug Mart Inc. (“Shoppers”), a subsidiary of Shoppers Drug Mart Inc., to become a supplier of cannabis products through its online platform. The agreement will see Auxly’s suite of products and brands, including chewables, chocolates, vapes and oil in a bottle, all developed and manufactured at Dosecann, available to consumers across Canada. Dosecann has completed its initial shipment of cannabis products to Shoppers.

“Having our diverse cannabis product offering with Shoppers allows us to reach a wide group of patients across the country with our quality, science-backed products,” said Hugo Alves, CEO of Auxly. “We are proud to partner with Shoppers and look forward to bringing their customers our products, built on Dosecann’s pillars of quality, safety and efficacy.”

Greg Boone, CEO of Dosecann, added: “Our team at Dosecann prides itself on manufacturing products backed by science and advanced research and development to ensure that consumers get the high-quality cannabis products that they need. We think this achievement is a testament to the extraordinary team that we’ve assembled and the rigor and precision that we apply to product development and manufacturing.”

The agreement is for a three-year term, subject to renewal for an additional two years.

About Dosecann LD Inc. Dosecann, a wholly-owned subsidiary of Auxly, is a Canadian developer and manufacturer of innovative cannabis products for the wellness-focused consumer. Dosecann is committed to providing Canadians with quality products designed for everyday use, backed by science and advanced research. Dosecann’s 52,000 square foot, GMP-compliant facility located in Charlottetown, Prince Edward Island, houses extraction, research and development, product formulation, analytical testing and commercial manufacturing for Auxly’s branded cannabis products. Built on the pillars of quality, safety and efficacy, Dosecann is cannabis – down to a science™.

About Auxly Cannabis Group Inc. (TSX.V: XLY) (OTCQX: CBWTF) Auxly is an international cannabis company dedicated to bringing innovative, effective, and high-quality cannabis products to the medical, wellness and adult-use markets. Auxly’s experienced team of industry first-movers and enterprising visionaries has secured a diversified supply of raw cannabis, strong clinical, scientific and operating capabilities and leading research and development infrastructure in order to create trusted products and brands in an expanding global market.

Learn more at www.auxly.com and stay up to date at Twitter: @AuxlyGroup; Instagram: @auxlygroup; Facebook: @auxlygroup; LinkedIn: company/auxlygroup/.

Investor Relations:
For investor enquiries please contact our Investor Relations Team:
Email: IR@auxly.com
Phone: 1.833.695.2414

Media Enquiries (only):
For media enquiries or to set up an interview please contact:
Email: press@auxly.com

Posted in Cannabis, Clients

Auxly Acquires Exclusive Global Rights to Omega-Rich Ahiflower® Seed Oil for Use in Cannabis Products

Two Emergence clients: Dosecann and Nature’s Crops

Dosecann facility in Prince Edward Island

Auxly Cannabis Group Inc. (TSX.V – XLY) (“Auxly” or the “Company”), a leading consumer packaged goods company in the derivative cannabis market, is pleased to announce that its wholly owned subsidiary Dosecann LD Inc. (“Dosecann”) has entered into an agreement with Natures Crops International (“Natures Crops”), a vertically integrated grower and manufacturer of plant-based specialty oils, pursuant to which the Company will purchase the exclusive global rights to Ahiflower® oil for use in Auxly’s diverse portfolio of cannabis products. This multi-year deal will provide Auxly with a proprietary ingredient for use in its current portfolio of cannabis products and the development of next generation cannabis health products that Auxly will commercialize when legally permitted.

“Auxly is committed to bringing innovative and differentiated cannabis products to consumers and this agreement provides our incredible team of scientists with a vegan, complete and balanced omega-rich proprietary ingredient with which to develop exciting products specifically targeted for the wellness consumer segment,” said Hugo Alves, Chief Executive Officer, Auxly.

Nature’s Crops AHIFLOWER® Seed Oil

Ahiflower starts as a non-GMO oilseed crop grown exclusively in the United Kingdom by Natures Crops. After harvesting the Ahiflower seeds, they are cold pressed to produce a crude oil that is exported to Canada where it is further refined into Ahiflower oil at the Natures Crops facility in Kensington, PEI. Ahiflower is a sustainable and traceable vegan polyunsaturated omega 3-6-9 oil, providing an ecologically-sound alternative to fish oils – each acre of Ahiflower produces as much omega-rich oil as 320,000 anchovies. Ahiflower oil contains more combined omegas than other natural plant or seed oils and contains a combination of the elements found in fish, evening primrose, olive, and flax seed oils. “Consumers seeking the utmost in excellence, freshness and traceability in Canadian, science-backed cannabis solutions will find Dosecann’s products compelling,” said Greg Cumberford, VP Science & Regulatory, Natures Crops.

Bob Chapman, Chief Science Officer at Dosecann, added: “Ahiflower oil provides a rich spectrum of naturally occurring omega 3-6-9 fatty acids to complement our cannabinoids, and we look forward to collaborating with the talented team at Natures Crops on research and development for novel cannabis-based solutions to meet consumers’ wellness needs.”

Ahiflower oil is a proprietary, licensed ingredient. In Canada, Ahiflower oil is a registered natural health product and non-GMO certified. It has been approved as a novel food in the European Union and has cleared FDA review status without objection in the United States.

About Natures Crops International

A manufacturer of specialty oils for dietary supplements, nutraceuticals, food, and personal care products, Natures Crops produces oils from the highest quality crops, produced by growers who follow strict management protocols for sustainability and identity preservation. Natures Crops ensures the crops produced are grown, processed, packaged, and delivered in a safe, sustainable, traceable, and cost-competitive manner. The company has operations in Prince Edward Island, Canada and the United Kingdom, with headquarters in North Carolina. Natures Crops is a member of the Council for Responsible Nutrition (CRN). For more information please write to info@naturescrops.com

About Dosecann LD Inc.

Dosecann, a wholly owned subsidiary of Auxly, is a Canadian developer and manufacturer of innovative cannabis products for the wellness-focused consumer. Dosecann is committed to providing Canadians with quality products designed for everyday use, backed by science and advanced research. Dosecann’s 52,000 square foot, GMP-compliant facility located in Charlottetown, Prince Edward Island, houses extraction, research and development, product formulation, analytical testing and commercial manufacturing for Auxly’s branded cannabis products. Built on the pillars of quality, safety and efficacy, Dosecann is cannabis – down to a science™.

About Auxly Cannabis Group Inc. (TSX.V: XLY) (OTCQX: CBWTF)

Auxly is an international cannabis company dedicated to bringing innovative, effective, and high-quality cannabis products to the medical, wellness and adult-use markets. Auxly’s experienced team of industry first-movers and enterprising visionaries has secured a diversified supply of raw cannabis, strong clinical, scientific and operating capabilities and leading research and development infrastructure in order to create trusted products and brands in an expanding global market.

Learn more at www.auxly.com and stay up to date at Twitter: @AuxlyGroup; Instagram: @auxlygroup; Facebook: @auxlygroup; LinkedIn: company/auxlygroup/.

Investor Relations:
For investor enquiries please contact our Investor Relations Team:
Email: IR@auxly.com
Phone: 1.833.695.2414

Media Enquiries (only): 

For media enquiries or to set up an interview please contact:
Email: press@auxly.com

Posted in Cannabis, Clients